Rectal cancer is a common malignant tumor of the digestive tract, and most patients with locally advanced stage cannot be directly surgically removed. Neoadjuvant therapy can reduce the tumor staging of patients, and then accept surgical treatment, improve the quality of life and the prognosis. Bevacizumab can inhibit the formation of tumor angiogenesis, in recent years, it has been used in neoadjuvant therapy for locally advanced rectal cancer, and has achieved certain clinical efficacy. In this summary, we have reviewed the recent literatures on bevacizumab in neoadjuvant therapy for locally advanced rectal cancer, and summarized them to provide some references for clinical application.

Yuna Guo. Application Progress of Bevacizumab in Neoadjuvant Therapy for Locally Advanced Rectal Cancer. Frontiers in Medical Science Research (2023) Vol. 5, Issue 3: 45-48. https://doi.org/10.25236/FMSR.2023.050307.

[1] American Cancer Society Cancer Statistics 2021 Report. J Nucl Med, 2021,62(3):12N.

[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66(2):115-32.

[3] Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin, 2020,70(3):145-164.

[4] Salvatore L, Bria E, Sperduti I, et al. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. Cancer Treat Rev, 2021,97:102202.

[5] Taïeb J, Aranda E, Raouf S, et al. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. Clin Colorectal Cancer, 2021,20(1):42-51.e3.

[6] Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol, 2017,12(5):599-610.

[7] Zhou M, Yu P, Qu J, et al. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis. Cell Physiol Biochem, 2016,40(1-2):361-369.

[8] Jiang Shijian. Application Progress of Bevacizumab in Neoadjuvant Therapy of Locally Advanced Rectal Cancer[J], Journal of Modern Medicine & Health, 2014, 30(4): 535-538. 

[9] Wan Desen, Zhang Suzhan, Chen Yuze, et al. The short-term and long-term effects of bevacizumab need to be confirmed by further clinical studies, and further studies are needed to confirm which radiotherapy and chemotherapy regimens have more significant effects. [J]. Journal of Practical Oncology, 2018, 33(1):41-46.

[10] Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. JAMA Oncol, 2017,3(7):e170278.

[11] Ruan WC, Che YP, Ding L, et al. Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer. Comb Chem High Throughput Screen, 2018,21(10):718-724.

[12] Kanat O, Ertas H. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. World J Clin Oncol, 2019,10(2):52-61.

[13] Xu W, Gong Y, Kuang M, et al. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. Clin Drug Investig, 2017,37(2):155-165.

[14] Eryılmaz MK, Mutlu H, Salim DK, et al. Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. J Oncol Pharm Pract, 2016,22(6):806-810.

[15] Pinto C, Antonuzzo L, Porcu L, et al. Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Clin Colorectal Cancer, 2017,16(2):e61-e72.